Huahai Pharma Set to Launch IL-17 Antibody HB0017 Clinical Study for HS
China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) is poised to initiate a clinical study...
Auto-immune
Chongqing Genrix’s Xeligekimab Approved for Ankylosing Spondylitis by NMPA
China-based Chongqing Genrix Bio Pharmaceutical Co., Ltd (SHA: 688443) has announced receiving approval from the...
Fosun Pharma Initiates Phase II Study for Glomerular Disease Treatment
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced the initiation of...
Hengrui Pharmaceuticals Gets NMPA Approval for SHR-1819 Phase II Study
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that it has received the...
MabPharm’s CMAB807 Biosimilar Infliximab Approved in Pakistan
Taizhou-based monoclonal antibody (mAb) biosimilar specialist MabPharm Ltd (HKG: 2181) has announced the receipt of...
NMPA Grants Conditional Approval for China’s First MSCs Therapy for aGVHD
The National Medical Products Administration (NMPA) in China has conditionally approved amimestrocel from Beijing-based Platinum...
Prime Gene Therapeutics Secures Over RMB300 Million in Series B Financing
Beijing-based Prime Gene Therapeutics Co., Ltd (873969.NQ), a clinical-stage biotech company specializing in immune inflammatory...
MabPharm’s CMAB807 Biosimilar Receives Market Approval in Indonesia and Peru
Taizhou-based MabPharm Ltd (HKG: 2181), a specialist in monoclonal antibody (mAb) biosimilars, has announced the...
Johnson & Johnson Secures Licensing Deal with Kaken Pharmaceutical for STAT6 Program
US giant Johnson & Johnson (J&J, NYSE: JNJ) has announced an exclusive licensing agreement with...
Henlius Biotech Expands Partnership with Palleon Pharmaceuticals for Autoimmune Disease Treatment
Shanghai Henlius Biotech Inc. (HKG: 2696), a leading biotechnology company based in China, has announced...
Everest Medicines’ Velsipity NDA for Ulcerative Colitis Accepted by China’s NMPA
China-based Everest Medicines (HKG: 1952) has announced that the National Medical Products Administration (NMPA) has...
Johnson & Johnson Submits sBLA to FDA for Simponi in Pediatric Ulcerative Colitis
US pharmaceutical major Johnson & Johnson (J&J, NYSE: JNJ) has announced the submission of a...
Accropeutics Gets FDA Green Light for Phase II UC Study of RIPK2 Inhibitor AC-101
Accropeutics Inc., a clinical-stage biotechnology company with operations in New York, US, and Suzhou, China,...
EMA’s CHMP Supports Approval of Eli Lilly’s Omvoh (Mirikizumab) for Crohn’s Disease
The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) has recently...
Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for Lupus Nephritis Clinical Trial
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that it has obtained approval from...
Abbisko Therapeutics Presents Positive Phase II Results for Pimicotinib in cGvHD at ASH
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) announced the presentation of preliminary Phase II...
InventisBio’s Oral TYK2 Inhibitor D-2570 Achieves Positive Results in Phase II Psoriasis Study
China-based InventisBio (Shanghai) Co., Ltd (SHA: 688382) has announced the successful completion of a Phase...
UCB Partners with BioRay Biopharmaceutical for Bimzelx Commercial Promotion in China
Belgium based UCB (EBR: UCB) is fulfilling its commitment to enhance attention to innovative products...
ImmuneOnco Biopharmaceuticals Receives NMPA Approval for Lupus Nephritis Phase II Study
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG: 1541), a China-based biopharmaceutical company, has announced receiving approval from...
Thederma’s TAP-1503 Cream Approved by China’s NMPA for Atopic Dermatitis Treatment
China-based Thederma has announced that its TAP-1503 cream has been granted approval by the National...